Older adults with metabolic fatty liver disease who started a class of diabetes and weight-loss medicines had fewer liver ...

Researchers have engineered salamander-inspired gold-silver nanocages that cascade-target injured kidney cells and their ...

GLP-1 RAs outperformed mineralocorticoid receptor antagonists (MRAs) in cardiovascular protection in resistant hypertension and obesity.

Quinolinic acid exacerbates maladaptive kidney damage and fibrosis, suggesting it as a contributor in AKI-to-CKD progression.

Companies are required to warn that experimental peptides, which haven’t been approved by the FDA, are for research use only.

So does microdosing GLP-1 medications actually work? A study published in August 2026 in Biology Methods and Protocols offers one of the largest real-world looks yet. People who stayed on the lowest ...

A new review argues that the mitochondrial peptide MOTS-c acts as a context-dependent stress signal with protective roles in ...

Read all the updates from day 2 of Breakthrough T1D's Clinical and Research Congress focused entirely on type 1 diabetes.

Heart and kidney complications remain a major concern for people living with type 1 diabetes (T1D). While there are some therapies available to reduce the risk of these complications, the T1D ...

The dialogue on health optimization, rapid physical recovery and longevity has been transformed across social media.

Share on Pinterest A new study shows a 33-fold increase in new BPC-157 users in recent years. Compassionate Eye Foundation/Jonathan Bielaski/DigitalVision/Getty Images Proponents of BPC-157, the ...

The Medical Possibilities Opened by Two PeptidesIn 2026, research into GLP-1 and orexin is attracting attention as a result ...